Molecular Therapy · 2008 · 194 citations · 16 references
PharmacyOncologyPharmaceuticsDrug DeliveryMetastasisNanoparticle Drug DeliveryCancer Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomedicineNucleic Acid DeliveryTargeted Cancer TherapyCancer NanotherapyCationic LiposomesLiposomesMetastasis ModelsOncogene RegulationSystemic DeliverySystemic Drug DeliveryVascular Endothelial Growth Factor
The selective delivery of small interfering RNA (siRNA) to metastatic tumors remains a challenging task. We have developed a nanoparticle (NP) formulation composed of siRNA, a carrier DNA, a polycationic peptide, and cationic liposomes. The NP was obtained by a self-assembling process, followed by surface modification with a polyethylene glycol (PEG)-conjugated ligand, anisamide. The NP was PEGylated and a ligand was presented to target sigma receptor–expressing murine melanoma cells, B16F10. The lung metastasis model was established by intravenous (IV) injection of the B16F10 cells into C57BL/6 mice. A mixture of siRNA against MDM2, c-myc, and vascular endothelial growth factor (VEGF) co-formulated in the targeted NP caused simultaneous silencing of each of the oncogenes in the metastatic nodules. Two consecutive IV injections of siRNA in the targeted NP significantly reduced the lung metastasis (∼70–80%) at a relatively low dose (0.45 mg/kg), whereas free siRNA and the nontargeted NP showed little effect. This targeted NP formulation significantly prolonged the mean survival time of the animals by 30% as compared to the untreated controls. At the therapeutic dose, the targeted NP showed little local and systemic immunotoxicity and did not decrease the body weight or damage the major organs. The selective delivery of small interfering RNA (siRNA) to metastatic tumors remains a challenging task. We have developed a nanoparticle (NP) formulation composed of siRNA, a carrier DNA, a polycationic peptide, and cationic liposomes. The NP was obtained by a self-assembling process, followed by surface modification with a polyethylene glycol (PEG)-conjugated ligand, anisamide. The NP was PEGylated and a ligand was presented to target sigma receptor–expressing murine melanoma cells, B16F10. The lung metastasis model was established by intravenous (IV) injection of the B16F10 cells into C57BL/6 mice. A mixture of siRNA against MDM2, c-myc, and vascular endothelial growth factor (VEGF) co-formulated in the targeted NP caused simultaneous silencing of each of the oncogenes in the metastatic nodules. Two consecutive IV injections of siRNA in the targeted NP significantly reduced the lung metastasis (∼70–80%) at a relatively low dose (0.45 mg/kg), whereas free siRNA and the nontargeted NP showed little effect. This targeted NP formulation significantly prolonged the mean survival time of the animals by 30% as compared to the untreated controls. At the therapeutic dose, the targeted NP showed little local and systemic immunotoxicity and did not decrease the body weight or damage the major organs.
16
Peter C. Scacheri, Orit Rozenblatt–Rosen, Natasha J. Caplen et al. · Proceedings of the National Academy of Sciences · 2004 · 609 citations · Full text
Siwen Hu‐Lieskovan, Jeremy D. Heidel, Derek W. Bartlett et al. · Cancer Research · 2005 · 565 citations
Medicine, Oncology, Pharmacology +17
Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Shyh‐Dar Li, Yun-Ching Chen, Michael Hackett et al. · Molecular Therapy · 2007 · 326 citations · Full text